These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 19931080

  • 1. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 2. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, Diamanti-Kandarakis E.
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [Abstract] [Full Text] [Related]

  • 3. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF.
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [Abstract] [Full Text] [Related]

  • 4. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 5. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 6. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F.
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [Abstract] [Full Text] [Related]

  • 7. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [Abstract] [Full Text] [Related]

  • 8. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL, Yang HY, Zhao JZ, Lin JJ, Lin WQ.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
    Bhattacharya SM, Jha A.
    Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
    [Abstract] [Full Text] [Related]

  • 10. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I.
    Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
    [Abstract] [Full Text] [Related]

  • 11. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
    Cinar N, Harmanci A, Bayraktar M, Yildiz BO.
    Clin Endocrinol (Oxf); 2013 Mar; 78(3):379-84. PubMed ID: 22509734
    [Abstract] [Full Text] [Related]

  • 12. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
    Gode F, Karagoz C, Posaci C, Saatli B, Uysal D, Secil M, Akdeniz B.
    Arch Gynecol Obstet; 2011 Oct; 284(4):923-9. PubMed ID: 21140159
    [Abstract] [Full Text] [Related]

  • 13. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M.
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [Abstract] [Full Text] [Related]

  • 14. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
    Wang QY, Song Y, Huang W, Xiao L, Wang QS, Feng GM.
    Chin Med J (Engl); 2016 Apr 20; 129(8):883-90. PubMed ID: 27064030
    [Abstract] [Full Text] [Related]

  • 16. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
    Kaya MG, Calapkorur B, Karaca Z, Yildirim S, Celik A, Akpek M, Unluhizarci K, Kelestimur F.
    Clin Endocrinol (Oxf); 2012 Dec 20; 77(6):885-92. PubMed ID: 22563947
    [Abstract] [Full Text] [Related]

  • 17. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L, de Zegher F.
    J Clin Endocrinol Metab; 2004 Apr 20; 89(4):1592-7. PubMed ID: 15070917
    [Abstract] [Full Text] [Related]

  • 18. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
    Mitkov M, Pehlivanov B, Terzieva D.
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb 01; 118(2):209-13. PubMed ID: 15653205
    [Abstract] [Full Text] [Related]

  • 19. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
    Meyer C, McGrath BP, Teede HJ.
    Diabetes Care; 2007 Mar 01; 30(3):471-8. PubMed ID: 17327307
    [Abstract] [Full Text] [Related]

  • 20. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF.
    Hum Reprod; 2008 Jul 01; 23(7):1594-601. PubMed ID: 18375410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.